Exogenous aldehydes can cause pain in animal models, suggesting that aldehyde dehydrogenase-2 (ALDH2), which metabolizes many aldehydes, may regulate nociception. To test this hypothesis, we generated a knock-in mouse with an inactivating point mutation in ALDH2 (ALDH2*2), which is also present in human ALDH2 of~540 million East Asians. The ALDH2*1/*2 heterozygotic mice exhibited a larger response to painful stimuli than their wild-type littermates, and this heightened nociception was inhibited by an ALDH2-selective activator (Alda-1). No effect on inflammation per se was observed. Using a rat model, we then showed that nociception tightly correlated with ALDH activity (R 2 = 0.90) and that reduced nociception was associated with less early growth response protein 1 (EGR1) in the spinal cord and less reactive aldehyde accumulation at the insult site (including acetaldehyde and 4-hydroxynonenal). Further, acetaldehyde-and formalin-induced nociceptive behavior was greater in the ALDH2*1/*2 mice than in the wild-type mice. Finally, Alda-1 treatment was even beneficial when given after the inflammatory agent was administered. Our data in rodent models suggest that the mitochondrial enzyme ALDH2 regulates nociception and could serve as a molecular target for pain control, with ALDH2 activators, such as Alda-1, as potential non-narcotic, cardiac-safe analgesics. Furthermore, our results suggest a possible genetic basis for East Asians' apparent lower pain tolerance.
INTRODUCTION
Pain is an international health problem, affecting about one in every five individuals (1) . About 200 million opioid prescriptions are written annually in the United States, and in 2013, vicodin was the overall number one prescribed medication (2) . According to the National Center for Health Statistics data recently released for 2010, opioid drugs caused 75% of all drug-induced deaths and were responsible for 16,651 fatalities (3) . Secondary health complications, including opioid abuse and dependence, afflict 2.1 million people (4) . In addition, nonsteroidal anti-inflammatory pain medications (NSAIDs) are used by over 30 million people each day in the United States for analgesia (5) . Yet, NSAIDs and cyclooxygenase-2 (COX-2) inhibitors also increase the risk of gastrointestinal bleeding and cardiac events, and their safety has been questioned for certain patient populations, such as those with cardiac disease (6, 7) . Thus, new molecular targets that regulate pain are needed to develop therapeutics for pain control with fewer deleterious addictive and cardiovascular effects.
Reactive aldehydes, including 4-hydroxynonenal (4-HNE), formaldehyde, and acetaldehyde, cause pain when directly applied in rodents (8) (9) (10) . We therefore determined whether altering the enzymatic activity of the mitochondrial aldehyde dehydrogenase-2 (ALDH2), which catalyzes removal of these reactive aldehydes, alters pain responses. We were also interested in this question because a common inactivating point mutation in mitochondrial ALDH2 (Glu 487 to Lys 487 ), found in 36% of Han Chinese, affects about 8% of the world population (11) . The ALDH2*2 in the Han Chinese codes for a dominant-negative variant reducing ALDH2 enzymatic activity by~60 to 80% in heterozygotes (ALDH2*1/*2) and by~95% in homozygotes (ALDH2*2/*2) compared to wild-type ALDH2*1/*1 (11) . The ALDH2*2 variant causes flushing after ethanol consumption, a result of acetaldehyde accumulation (11) . The ALDH2*2 inactivating mutation also causes reduced metabolism of other reactive aldehydes, including malondialdehyde (MDA) and 4-HNE (12) , and the rate of formaldehyde metabolism in human mitochondrial liver fractions from ALDH2*1/*2 subjects is about three times slower than in those from ALDH2*1/*1 subjects (13) .
Our laboratory has developed a small molecule that selectively enhances the activity of ALDH2, Alda-1 [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide] (14) . Alda-1 corrects the structural defect in the mutant ALDH2*2, thereby increasing ALDH2*2 activity (15) . Here, we determined whether ALDH2 enzymatic activity modulates acute inflammatory-induced hyperalgesia and whether the ALDH2 activator Alda-1 could be a potential drug to reduce pain.
RESULTS
We generated knock-in mice carrying the inactivating Lys 487 point mutation in ALDH2, identical to the mutation found in Han Chinese [(11); denoted ALDH2*2] ( fig. S1 ). To confirm that the mutant mice mimic the human phenotype, we challenged them with ethanol and determined blood acetaldehyde levels. Similar to human heterozygotes (16) , heterozygote mice accumulated five times higher blood acetaldehyde concentrations than did wild-type ALDH2 (ALDH2*1/*1) mice (Fig. 1A) . Before nociceptive testing, we performed behavioral tests to confirm that the ALDH2 inactivating mutation did not affect mouse gross motor skills. No differences were detected in the mean number of squares crossed in an open field (Fig. 1B ) or in rearing behavior (Fig. 1C) between wild-type and ALDH2*1/*2 mice. Similarly, in a rotarod test, no differences were seen between wild-type and ALDH2*1/*2 mice (Fig.  1D and fig. S2 ). When assessed in liver tissue homogenate, the abundance of ALDH2*1/*2 protein was about 44% lower than that in wildtype mice (Fig. 1E) , and ALDH activity in the heterozygotic mice was All data are means ± SEM; *P < 0.01 compared to WT given water, ◊ P < 0.01 compared to all other groups, † P < 0.05 compared to WT, as assessed by t test (B, C, E, and F), one-way analysis of variance (ANOVA) (A), and two-way ANOVA (D). Red arrows indicate treatment either with vehicle or with the ALDH2 activator Alda-1 (2 mg/kg, subcutaneously). At time zero (black arrow), carrageenan (Car) (100 mg) was injected to the right hind paw. (B) Nociceptive threshold in mice assessed at baseline and 3 hours after carrageenan-induced inflammatory insult using the up-down technique (n = 8 animals per group, tested once per animal). (C) A representative Western blot and percent change in 4-HNE protein adducts in proteins extracted from paws treated with saline or with carrageenan from WT and heterozygous ALDH2*1/*2 mice [n = 8 animals per group; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control]. (D) In a separate subset of mice, nociceptive threshold was assessed with a scoring scale 3 hours after the inflammatory insult (2, no response; 1, withdrawal from stimulus; 0, immediate withdrawal from stimulus with licking or flinching) (n = 6 to 7 animals per group, repeated six times per animal). The observers were blinded to the experimental conditions. Baseline measurements for (D) are provided in fig. S3 . (E) Nociceptive threshold for WT and ALDH2*1/*2 mice after administration of Alda-1 (2 mg/kg per treatment) as assessed by the scoring technique used in (D) (n = 8 animals per group, repeated six times per animal). Additional data for other von Frey hairs tested are provided in fig. S3 . All data are expressed as means ± SEM; *P < 0.05 compared to WT and ◊ P < 0.05 compared to all other groups, as assessed by ANOVA with Tukey's correction; behavioral analyses were carried out by observers blinded to the experimental conditions. 20% that of wild-type animals (Fig. 1F ). These characteristics of the ALDH2*1/*2 protein in the heterozygotic mice were similar to those described for human heterozygotes (17) .
We next assessed nociception in ALDH2*1/*2 mice that had received carrageenan injections in the hind paw and compared their responses to those of wild-type littermates ( Fig. 2A) . The ALDH2*1/*2 untreated mice had lower ALDH2 levels in their paws than did wild-type mice ( fig. S3A ), similar to the liver homogenates (Fig. 1E) . Mouse pain behavior, assessed by an observer blinded to the experimental conditions, was measured by applying von Frey filaments at known force to elicit paw withdrawal, by an "up-down" method (details in Materials and Methods). We observed no differences in baseline nociceptive behavior between wild-type and ALDH2*1/*2 mice (Fig. 2B) . After carrageenan injection to induce acute inflammatory pain, the ALDH2*1/*2 mice exhibited a larger hyperalgesia response than did wild-type mice (Fig. 2B) . Carrageenan administration also increased the accumulation of 4-HNE adducts in the paw, with the ALDH2*2 mice having higher 4-HNE adduct levels than the wild-type mice (Fig. 2C) . When we used a nociceptive response scoring method for quantification of nociceptive pain responses (18), we also saw that the ALDH2*1/*2 mice exhibited increased hyperalgesia in response to each von Frey hair tested ( Fig. 2D  and fig. S3B ). Administration of the ALDH2 activator Alda-1 (2 mg/kg per treatment) reduced the response to the nociceptive stimulus in the heterozygous ALDH2*1/*2 mice for each von Frey hair tested [ Fig. 2E  and fig. S4 , A to E; baseline (untreated) values are provided in fig. S4A ]. Moreover, Alda-1 reversed the behavioral response to the carrageenaninduced insult, restoring thresholds to baseline values for both wildtype and ALDH2*1/*2 mice, when assessed by the up-down method ( fig. S4F ) (baseline: wild type, 1.5 ± 0.1 g and ALDH2*1/*2, 1.6 ± 0.2 g; 3 hours after carrageenan: wild type, 1.7 ± 0.4 g and ALDH2*1/*2, 1.3 ± 0.2 g; mean ± SEM, n = 8 per group). When Alda-1 was given to wildtype mice alone, without an inflammatory insult, no changes were noted in behavioral response ( fig. S4G ). We confirmed Alda-1 selectivity for ALDH2 by testing in vitro its effect on the activity of five other ALDH enzymes (14) (table S1).
To further investigate how ALDH2 activity may regulate nociception, we used a rat model of inflammatory pain by measuring a rat nociceptive response after injection of an inflammatory stimulus in the hind paw (protocol; Fig. 3A ). When given alone without an inflammatory stimulus, Alda-1 had no effects on response to thermal stimuli (defined as time lapsed after a change in thermal stimulus, or thermal latency) (Fig. 3B) . Similarly, Alda-1 did not affect basal sensitivity to mechanical stimulus as assessed with the Randall-Selitto test, in which the amount of weight in grams applied to the rat paw is incrementally increased (70 ± 2 g versus 73 ± 1 g, with and without Alda-1, respectively; n = 10, Alda-1 group; n = 6, vehicle group). However, when carrageenan was injected in one paw, Alda-1 doubled the latency time to thermal stimulation of that paw (Fig. 3B) . Additionally, Alda-1 doubled the nociceptive threshold to mechanical stimulation: rats withdrew their inflamed paw at 45 g of pressure in the absence of Alda-1; after Alda-1 treatment, they withdrew their paw only after 90 g of pressure was applied (Fig. 3C , y-axis values). Similar data were observed when prostaglandin E 2 (PGE 2 ), instead of carrageenan, was used to induce nociception (Fig. 3C , y-axis values). In each condition, ALDH activity in the paw correlated with nociceptive threshold (R 2 = 0.90; Fig. 3C ). To test whether the Alda-1 reduction in nociception was a result of an anti-inflammatory effect, we measured carrageenan-induced edema of the paw and found that inflammation was unaltered by Alda-1 treatment (Fig. 4, A and B) . Carrageenan administration caused a~50% increase in paw volume over the untreated contralateral paw of vehicletreated rats, and this increase was unaffected by Alda-1 treatment (Fig.  4A) . Further, markers of inflammation, including mast cell chymase ( Fig. 4B ) and neutrophil elastase (267 ± 61 versus 220 ± 26 relative units determined by Western blot; fig. S5 ), increased equally in the vehicle-treated and Alda-1-treated carrageenan groups. In contrast, the levels of early growth response protein 1 (EGR1), a central nervous system marker of hyperalgesia (19) , increased about fivefold in the L4 to L6 spinal cord dorsal horn superficial laminae, and the increase in EGR1 levels was brought back to basal levels by Alda-1 treatment (Fig. 4C ). We also found that 4-HNE protein adducts and MDA levels were elevated in the inflamed paw and that these levels declined after activator Alda-1 (2 mg/kg, subcutaneously). At time zero (black arrow), the inflammatory insults (carrageenan or PGE 2 ) were given to the right hind paw. (B) Latency to thermal stimulation for rat hind paw withdrawal with and without treatment with Alda-1. (C) Nociceptive threshold in rats subjected to carrageenan or PGE 2 proinflammatory insults. All data are expressed as means ± SEM; *P < 0.01 compared to untreated and Alda-1 alone group and ◊ P < 0.01 compared to all other groups, as assessed by ANOVA with Tukey's correction (B) and linear regression (C); n = 6 to 8 animals per group, tested once per animal; the observers were blinded to the experimental conditions. Alda-1 treatment (Fig. 4 , D and E). Thus, inflammation-induced aldehydic load, but not the inflammation response, was decreased by Alda-1-induced activation of ALDH2.
ALDH2 metabolizes acetaldehyde, so we therefore measured this aldehyde in the paws of our animals. Unexpectedly, acetaldehyde was detected in the paws, and carrageenan doubled its levels (Fig. 5A ). Alda-1 treatment decreased acetaldehyde to basal values (Fig. 5A) . Because acetaldehyde accumulated during the carrageenan-induced inflammatory insult, we determined whether direct administration of acetaldehyde to the paw induced nociception. Acetaldehyde caused an immediate effect on pain behavior, as assessed by paw flinching and licking, in a dose-dependent manner (Fig. 5B) . Further, injection of acetaldehyde (600 ng), but not vehicle, in the paw decreased the nociceptive threshold, an effect that declined by 30 min and dissipated by 3 hours after injection (Fig. 5C ).
The ALDH2*1/*2 mice spent slightly more time flinching and licking after acetaldehyde injection compared to the wild-type mice, but this was likely biologically insignificant, because the difference was only about 1 s (Fig. 5D ). More importantly, the acetaldehyde injection lowered the nociceptive threshold in the ALDH2*1/*2 mice and extended the duration of nociceptive behavior compared to the wild-type ALDH2*1/*1 mice (Fig. 5E) .
We next subjected both wild-type ALDH2*1/*1 and heterozygous ALDH2*1/*2 mice to nociception induced by formalin (2%, aqueous formaldehyde) injection into the paw. The formalin-induced nociceptive response occurs in two phases: an immediate phase (0 to 9 min) and a more sustained phase 2 (10). After injection, we noted extended phase 2 flinching and licking behavior (Fig. 5F ) but no differences in phase 1 ( fig. S6 , A and C) between ALDH2*1/*2 mice and ALDH2*1/*1 wild-type mice, with phase 2 lasting 30 min longer in ALDH2*1/*2 mice than in formalin-injected wild-type mice ( fig. S6A ). The increase in cumulative flinching and licking behavior in phase 2 was largely a result of changes in IIb ( fig. S6D ). The formalin-induced flinching during phase 2 was markedly reduced by Alda-1 treatment in both groups of mice ( Fig. 5F and  fig. S6D ).
We next determined whether Alda-1 treatment was beneficial when given to rats after the inflammatory condition was established (Fig. 6A) . We found that Alda-1 increased the thermal latency and the nociceptive threshold even when injected after the inflammation-inducing carrageenan stimulus was administered (Fig. 6, B and C) . Thus, the beneficial effect of ALDH2 activators was not limited to prophylactic use. We also found that the antinociceptive effect of Alda-1 was not blunted in the presence of the opioid receptor antagonist naloxone (1 mg/kg per injection, given 10 min before Alda-1 treatment) (Fig. 6 , B and C), suggesting that it does not involve an opiate pathway.
DISCUSSION
Our study demonstrates that activation of ALDH2 with Alda-1 in two rodent models reduces nociception and that the ALDH2*2 inactivating mutation in mice, which mimics a human genotype present in 8% of the world population, increases the nociceptive response. We have previously found that activation of ALDH2 reduces cardiac injury after ischemic insult (14) and improves cardiac function in a rodent model of heart failure (20) . Here, we also show that the reduced nociception by Alda-1 treatment is insensitive to opiate receptor antagonists. Together, our data suggest that ALDH2 activators, such as Alda-1, may represent a non-narcotic, cardiac-safe class of therapeutic agents for acute inflammatory-induced pain.
Pain is a subjective feeling that can only be measured in animal models as a behavioral response to nociceptive stimulus. We used two different techniques to assess nociception in mice: a scoring system used by some East Asian laboratories (18) and the up-down technique used by the Western world (21) to study pain behavior in rodents. Further, because of the small paw volume in a mouse and the time required to breed a number of mice for our behavioral studies, we used a second model of pain in rats and performed more extensive studies in that model.
Reactive aldehydes, including MDA and 4-HNE, induce pain responses (22, 23) . These aldehydes are produced by reactive oxygen species-induced peroxidation of exogenous and endogenous polyunsaturated fatty acids. Blood levels of 4-HNE in healthy individuals (~0.5 mM) can increase 10 to 100 times under oxidative stress (24, 25) . Similar increases in MDA levels after oxidative stress have also been reported (26) . Although its main source is ethanol metabolism (27, 28) , acetaldehyde may be formed by pyruvate dehydrogenase in the mitochondria, and the accumulation of aldehydes impairs mitochondrial ALDH2 activity (14) ; these sources may have contributed to the acetaldehyde accumulation that we observed. Regardless, our data demonstrate the importance of ALDH2 in controlling the levels of reactive aldehydes, including 4-HNE, MDA, and acetaldehyde, and reducing pain sensation.
Although additional transgenic mice with alterations in ALDH2 exist, including a knockout ALDH2 mouse (29, 30) and an overexpressing ALDH2*2 mouse (31), the ALDH2*2 mice that we have generated are particularly suitable for preclinical and translational studies because they mimic the human ALDH2*2 point mutation. Like humans carrying the ALDH2*2 mutation, no noticeable gross motor differences were identified in mice with this mutation. In addition, ALDH2 protein levels and enzymatic activity in the heterozygotic mice were decreased similarly to these values in heterozygotic humans (17) .
A number of limitations to our study should be noted: We only studied ALDH2*1/ *2 heterozygotic, not homozygotic *2/*2, mice. We also did not determine whether the beneficial effect of Alda-1 treatment results from central or peripheral action, nor did we determine Alda-1 efficacy in chronic pain or arthritis. Nevertheless, because mice with this mutation exhibited reduced response to nociception after Alda-1 treatment, subjects with the ALDH2*2 variant may experience more severe inflammatory pain and benefit from drugs that activate ALDH2.
Known genetic mutations regulating pain sensation are limited to small familial subsets of the human population (32, 33) and to rare point mutations in ion channels (34, 35) . Our findings in rodents suggest that the ALDH2 point mutation ALDH2*2, present in 8% of the world population, might also contribute to lower pain thresholds in humans. The prevalence of the ALDH2*2 point mutation, which is unique to East Asian ethnicity, is~36% (11) and in some regions as high as 45% (36) . Asians are reported to have a lower pain tolerance than other ethnicities (37) (38) (39) (40) and are more responsive to painful stimuli such as skin irritation (39), capsaicin (40) , heat (41), cold (42), or mechanical stimulus (37) compared with other ethnic populations. Although these differences are ascribed primarily to social or cultural factors (38) , it is possible that increased pain sensitivity among Asians can be attributed, at least in part, to the ALDH2*2 mutation. Case reports provide further evidence for a role for ALDH2 in pain sensation, suggesting that the ALDH2 inhibitor disulfiram may cause painful peripheral neuropathy in a dose-dependent and reversible manner (43) . Nevertheless, our data in rodents indicating that ALDH2 activity attenuates nociception remain to be confirmed in humans.
Our findings that Alda-1 corrects ALDH2 inactivity due to the mutation in ALDH2*2 (15) suggest that compounds like Alda-1 may benefit East Asian and other populations in reducing inflammatory pain. The apparent non-opioid-dependent mechanism for Alda-1 would circumvent the potential for addiction and abuse seen with opioids used for analgesia (44) . Moreover, Alda-1 is beneficial when given during ischemic injury (14) and reduces ischemia-induced cardiac arrhythmias (45) . Although more studies are required, this non-opioid, cardiac-safe profile for Alda-1 may be particularly useful for patients with cardiac risk factors and known cardiac disease because the use of some traditional NSAIDs or COX-2 inhibitors was confirmed in a large metaanalysis to increase cardiovascular risk (7) .
In summary, our study identified ALDH2 as a regulator of acute nociception in rodents. Although confirmatory studies are needed, our rodent studies suggest that the ALDH2*2 mutation may underlie differences in pain behavior observed in humans. We showed that heterozygous mice with an ALDH2 inactivating mutation, ALDH2*1/*2, have increased reactive aldehyde-induced adducts and increased nociception when compared to wild-type mice; these effects were corrected by Alda-1 treatment. Increasing the activity of mitochondrial ALDH2 with Alda-1 reduced aldehydic load, limited changes in the marker of hyperalgesia EGR1, and provided analgesia. Our data suggest that activators of ALDH2, such as Alda-1, may be a promising therapeutic drug class to reduce pain that likely acts independently of opioid receptor signaling and without increasing cardiovascular risk.
MATERIALS AND METHODS

Study design
All procedures were in accordance with the guidelines of the International Association for the Study of Pain and approved by Stanford University (#25505) and the Butantan Institute, São Paulo, Brazil (CEUAIB #838).
The study objective tested whether ALDH2 regulated inflammatory pain in rodent models. We tested our hypothesis by using (i) ALDH2*1/*2 knock-in mice litter-matched to C57BL/6 wild-type ALDH2 mice; (ii) Wistar rats; (iii) an ALDH2 activator, Alda-1, which also corrects the decreased enzymatic activity of the ALDH2*1/*2 mutation; and (iv) inflammatory pain models by administering carrageenan, PGE 2 , acetaldehyde, or formalin to the rodent paw. We used both mechanical and thermal methods of nociception detection, in addition to biochemical analysis.
On the basis of our previous experience, a minimum of six rodents per group is required to obtain statistically meaningful behavioral data. An experimental group size of six or more animals is necessary to achieve at least a 20% minimal difference in behavior for a power of 95% with a < 0.05 and b < 20%. All behavioral tests were performed between 9:00 a.m. and 4:00 p.m. by observers blinded to the treatment groups. Male Wistar rats (170 to 190 g) and male mice (18 to 21 g) were housed in a temperature-and light-controlled room for at least 3 days before use. All animals were randomized and assigned to testing groups to generate biological replicates for each group, and the experimenter was blinded as to genotype and drug treatment given.
Drugs Saline (0.1 ml; control), carrageenan (200 mg for rats and 100 mg for mice; Marine Colloids), PGE 2 (100 ng, Sigma), or formalin (2%, Fig. 6 . Effect of Alda-1 after the inflammatory insult on nociceptive threshold. (A) Nociceptive threshold testing (closed circles) assessed by either the Hargreaves or the Randall-Selitto method at baseline and 3 hours after inflammatory insult. Red arrows, treatment with either vehicle or the ALDH2 activator Alda-1 (2 mg/kg, subcutaneously). Naloxone (Nal, 1 mg/kg) or vehicle was given subcutaneously (green arrows) 10 min before each Alda-1 treatment. At time zero (black arrow), the inflammatory insult (carrageenan) was given to the right hind paw. (B and C) Alda-1 was given 30 and 150 min after carrageenan (n = 9 per group, tested once per animal; *P < 0.0001 as assessed by ANOVA followed by Tukey's correction). Error bars represent means ± SEM. The observers were blinded to the experimental conditions. Sigma) was administered by intraplantar injection into the right hind paw to induce nociception. These doses were chosen on the basis of previous studies by our laboratory groups (46) and published literature (47) .
Alda-1 dose (2 mg/kg per injection, dissolved in 50% polyethylene glycol/50% dimethyl sulfoxide) was established in preliminary studies and given in multiple doses because of its estimated short half-life. Alda-1 was injected subcutaneously to the dorsal side of the neck 15 min before carrageenan or saline and again at 30 and 150 min after carrageenan, PGE 2 , or saline injection. One subset of animals received Alda-1 only 30 and 150 min after carrageenan injection. Where indicated, naloxone (1 mg/kg per injection, Sigma) or vehicle (saline) was given 10 min before each Alda-1 treatment to the dorsal side of the neck.
Knock-in mice generation (see also fig. S1 ) ALDH2*2 knock-in mice with a C57BL/6 background were generated by homologous recombination. The 8.0-kb genomic fragment encompassing the mouse ALDH2 locus was cloned to the gene-targeting vector pPNT to introduce a single amino acid substitution. Site-directed mutagenesis introduced a single nucleotide substitution (G to C) within exon 12 of the ALDH2 genomic fragment corresponding to the position of human E487K mutation. Plasmid DNA from the constructed pPNT vector was electroporated to embryonic stem (ES) cells. Positive ES clones were selected on the basis of neomycin and thymine kinase markers and confirmed by polymerase chain reaction (PCR), restriction fragment length polymorphism, and DNA sequencing. Positive ES cells were microinjected into C57BL/6 blastocytes and implanted into pseudopregnant females.
Germ-line transmission of the ALDH2 E487K mutation by homologous recombination was derived from selected ES cell lines from founder mice. The genotype of the E487K mutation was confirmed by direct genomic DNA sequencing of PCR fragments from amplified genomic DNA. The specific primers EG475 (TACTGTCAAAGTGCCACAGAAGAA-CTCGTAA), EG460 (AACCTGCGTGCAATCCATCTTGTTCAATGG), and EG399 (TTGGCCTTCCACTGGGA GTGGGTCCCTCTGTC) were used for the amplification of a 1.3-kb fragment from exon 13 to the 3′ untranslated region of neomycin marker and a 3.0-kb fragment from exon 13 to downstream of the neomycin marker, respectively, for the presence of the mutated allele. In contrast, for the wild-type allele, a 1.4-kb fragment devoid of the neomycin marker was amplified with EG475 and EG399 primers. We confirmed the expression of the ALDH2 E487K mutant protein, which exhibited a change in charge as a result of the glutamate-to-lysine substitution, by isoelectric focusing gel electrophoresis and Western blot with an ALDH2-specific antibody (Santa Cruz Biotechnology, 1:500). The founder mice were backcrossed to the C57BL/6 background for at least seven generations to achieve a homogeneous genetic background, and the E487K mutation was transmitted as a single Mendelian gene.
Nociception assessment
The experimental performer was blinded to both genotype and treatments. Nociceptive response was assessed by testing mechanical and thermal hypersensitivity. Mechanical sensitivity was measured by the von Frey method for mice and the Randall-Selitto method for rats immediately before and 180 min after carrageenan or PGE 2 injection. Thermal sensitivity was measured by the Hargreaves method. Both mice and rats were acclimated to the testing equipment 1 day before baseline testing.
To measure mechanical sensitivity, mice were placed individually in a plastic cage with a wire mesh bottom for testing. After acclimation to the plastic cage for at least 15 min, a von Frey hair was pressed perpendicularly against the plantar skin surface and held for about 5 s until the hair slightly buckled (36, 48) . Mice were randomly separated into two testing groups, one scored with the up-down technique and the other with a pain scoring system.
The up-down technique was performed as follows: Before and after carrageenan administration, von Frey hairs of increasing force were applied to the mice hind paw until the paw was withdrawn. Once a response was identified, the next lower von Frey hair was applied. For each positive response (paw withdrawal), the next lesser filament was tested. For each negative response, the next higher filament was tested. The sequence of positive and negative responses was recorded and incorporated in an established curve-fitting algorithm to determine mechanical sensitivity (49) .
The scoring system technique was performed as follows: Hind paw nociception was assessed with six different von Frey hairs (0.03, 0.17, 0.41, 0.69, 1.20, and 1.48 g). Using the same stimulation intensity as the 0.03-g von Frey hair, each individual hair was applied six times to each hind paw at intervals of several seconds. Because the response to each von Frey stimulus is fairly subjective, we used a method of objectifying these nociceptive responses by assigning a specific number to the response. The scoring system was as follows: 2, no response; 1, withdraws paw from hair; 0, immediate flinching or hind paw licking. This method was previously shown by others to provide a reliable, objective assessment of pain response using von Frey hairs (18, 50) .
Nociceptive threshold was also determined with the Randall-Selitto paw pressure test (Ugo Basile), as described (48) . The baseline values varied between 65 and 75 g of force. Animals with baseline out of this range (10%) were excluded before initiating the study to achieve uniform testing.
Thermal sensitivity, as assessed by hind paw withdrawal threshold, was measured by the Hargreaves method (51). Rats were placed in the apparatus to acclimate for 10 min. A light source was then applied to the hind paw, and the time until the rat withdrew the paw from the light source was assessed. A 30-s exposure time was used to limit thermal damage to the paw region, with light source intensity adjusted in preliminary studies to cause a latency response of 15 s in control rats.
Edema assessment. Inflammation-induced edema of the injected paw was assessed with a plethysmometer (Ugo Basile) (52) .
Evaluation of general motor activity (open field and rotarod). The general activity of ALDH2*1/*2 knock-in and wild-type mice was assessed in an open-field arena (Ugo Basile). Each animal was individually placed in the center zone, and behavioral parameters were recorded for 3 min (48). Hand-operated counters were used to tally the number of squares crossed and rearing behavior (number of times standing on hind legs). For rotarod testing, mice were trained at a fixed speed of 10 rpm for three consecutive days. Mice were then tested at different speeds, and latency to fall was measured. For the acceleration task, the rotarod was accelerated from 5 to 40 rpm over 5 min. The fall latency was recorded.
Blood acetaldehyde determination. Blood samples (50 to 100 ml) were drawn from the retro-orbital sinus under anesthesia. Levels of acetaldehyde were determined by a fluorescence-based high-performance liquid chromatography method, as described previously (53) .
Tissue acetaldehyde measurements. Paw samples were quickly sealed in microcentrifuge tubes and weighed, and 3 volumes (v/w) of Liberase TL (0.75 mg/ml) (Roche) was added for overnight digestion at 37°C. Acetaldehyde standard solutions (100 to 5000 ng/ml) and tissue samples were reacted with saturated 2,4-dinitrophenylhydrazine (DNPH) solution.
To establish liquid chromatography-tandem mass spectrometry (LC-MS/MS) conditions, a standard of acetaldehyde DNPH was used. Chromatograms of standards established characteristic retention times of acetaldehyde and verified that the MS signal was linear over the range of 0.1 to 5 mg/ml. The acetaldehyde peak area derivatives were calculated and plotted against the concentration of the calibration standards with Analyst 1.5.1 software.
Aliquots (30 ml) were taken from each paw homogenate sample. Acetaldehyde was extracted from samples of paw homogenate by adding 150 ml of methanol containing DNPH (40 mg/ml). Both unknown samples and standards were vortexed and centrifuged to separate the precipitate. Ten microliters of sample extracts was injected into LC-MS/MS for analysis. Automatic peak detection, integration, and data processing were performed by the AB SCIEX Analyst 1.5.1 software package. Concentrations of acetaldehyde were calculated by plotting peak area of unknown samples against a standard curve. The data were normalized to the paw volume obtained by plesthysmography.
Acetaldehyde experiments. Rats were acclimated to the test environment 15 min before experiments. Acetaldehyde (100, 300, and 600 ng/g of paw tissue) was diluted in saline containing 0.5% Tween 80 and injected intraplantarly. Hind paw licking and flicking behavior was quantified for 10 min. Immediately after this test, the paw threshold was assessed at 10, 15, 20, 30, and 180 min after acetaldehyde injection, using the Randall-Selitto test as described. For mice, acetaldehyde (100 ng/g of paw tissue) was injected intraplantarly, and licking and flicking behavior was quantified for 10 min. Immediately afterward, the paw threshold was assessed at 10, 30, 60, and 120 min, using the von Frey test as described.
Formalin experiments. Mice were placed individually in a plastic cage. After acclimation for~15 min, formalin (2%, 20 ml, in saline) was injected, and flinches as well as time spent licking the injected hind paw were recorded. Behavior was divided into phase 1 (0 to 10 min) and phase 2 (10 to 90 min), with phase 2 being further divided into phase 2a (10 to 40 min) and phase 2b (40 to 90 min) as described (10) . For a subset of experiments, Alda-1 was given once, 5 min before formalin was administered.
Biochemical studies for rats and mice One hundred eighty minutes after treatment, rat paw tissue was homogenized and centrifuged at 700g for 5 min at 4°C, and the pellet was discarded. Protein concentration in the supernatant was determined by Bradford assay.
ALDH enzymatic measurement ALDH enzymatic activity was determined as described (14) .
Western blot analysis
Western blot was performed as described (14) . For 4-HNE protein adduct detection, an antibody against the reductively stabilized 4-HNE amino acid adduct (Alpha Diagnostic Intl., 1:1000) was used. For mast cell chymase and neutrophil elastase, detection antibodies from Santa Cruz Biotechnology (1:500) were used. Quantification analysis of blots was performed with ImageJ software, using GAPDH as a loading control.
TBARS assay TBARS, which measures MDA, was performed with an OXItek TBARS assay kit (ZeptoMetrix). The concentration of TBARS was expressed in picomoles per milligram of protein by using a standard curve of MDA at 0 to 200 pmol concentrations and expressed as percent control.
Immunohistochemistry Animals were anesthetized with ketamine (90 mg/kg) and xylazine (15 mg/kg) after 3 hours of the experimental protocol. Subsequently, animals were perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4). Spinal cord sections (L4 to L6) were removed, post-fixed for 4 hours in PFA (4%), and transferred to a 30% sucrose solution in phosphate buffer to ensure cryoprotection. Spinal cords were sectioned (10 mm) on a cryostat and displayed on histological slides. The sections were immunostained for EGR1 gene expression, using a rabbit polyclonal antibody (Santa Cruz Biotechnology, 1:500) in phosphate buffer containing 0.3% Triton X-100 and 5% normal donkey serum overnight at 24°C. The sections were then washed in phosphate buffer and incubated with a biotinylated donkey antirabbit serum (Vector Labs, 1:200) in phosphate buffer for 2 hours at 24°C. The sections were washed again in phosphate buffer and incubated with the avidin-biotin-peroxidase complex (Elite ABC, Vector Labs). The sections were then reacted with 0.05% 3,3-diaminobenzidine and 0.01% hydrogen peroxide in phosphate buffer. Intensification was conducted with 0.05% osmium tetroxide in water. The sections were dehydrated, cleared, and mounted on a coverslip. Normal rat serum served as control. Digital images of light microscopy were collected, and cells with positive EGR were counted.
Statistical analysis
Data are expressed as means ± SEM. ANOVA with Tukey's post hoc analysis was used for behavioral pain studies and biochemical analysis. When only two groups were analyzed and compared, an unpaired t test was performed. For Fig. 3C , linear regression analysis and Pearson correlation testing were used to assess concordance. A value of P < 0.05 was considered significant. GraphPad Prism software was used for all statistical analysis.
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